October 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
Diagnosis & Disease Information
Epinephrine Nasal Spray Under Review for Emergency Tx of Severe Allergic Reactions
Intranasal epinephrine was found to be absorbed quicker.
Out-of-Pocket Costs for Epinephrine Auto-Injectors Examined
Cost-sharing still substantial for some using nonbranded auto-injectors, such as those enrolled in high-deductible health plans
Anaphylaxis Rare With IV Iron Use, But Risk Varies By Formulation
By clarifying the risk for anaphylaxis, study findings can contribute to the choice of IV iron preparations, according to investigators.
MPR Weekly Dose Podcast Episode 111
Allergy treatment gets over-the-counter approval; Anaphylaxis treatment recalled; Phase 3 trial results for investigational sciatica treatment; FDA alert regarding at-home COVID-19 tests; And the resubmitted Biologics License Application for teplizumab for type 1 diabetes is accepted.
Syringe Malfunction Prompts Recall of Anaphylaxis Treatment
Certain lots of Symjepi (epinephrine) Injection 0.15mg and 0.3mg prefilled single-dose syringes are being recalled.
Epinephrine Sublingual Film Fast Tracked for Emergency Tx of Allergic Reactions
The designation is supported by data from Part 1 of the EPIPHAST study, which compared the pharmacokinetics and pharmacodynamics of AQST-109 to intramuscular epinephrine in healthy adults.
Guidance Updated for Assessing Allergy Risk of COVID-19 Vaccines
Janssen adenovirus type 26 vectored vaccine may be considered for individuals who self-report PEG allergy
ACAAI Updates Guidance for Allergic Reactions to COVID-19 Vaccines
Guidance relates to risks for allergic reactions for mRNA (Moderna and Pfizer) and adenovirus vector (Johnson & Johnson) COVID-19 vaccines
Rates of Acute Allergic Reactions to COVID-19 Vaccines Extremely Low
Most recipients with anaphylaxis had allergy histories, with 31 percent having prior anaphylaxis
